Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Progesterone
Drug ID BADD_D01852
Description Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss [A175609]. Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization [T481], [A175612] as well as in other formulations to promote and support pregnancy. Please see [Medroxyprogesterone acetate], [Megestrol acetate], [Dydrogesterone] and [Hydroxyprogesterone] entries for information on various other forms of progesterone. Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin [FDA label]. Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes [Label,F3898,F3904,F3901,F3907].
Indications and Usage For progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency and for the treatment of secondary amenorrhea. Also used for the reduction of the incidence of endometrial hyperplasia and the attendant risk of endometrial carcinoma in postmenopausal women receiving estrogen replacement therapy, as well as treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as fibroids or uterine cancer.
Marketing Status Prescription; Discontinued
ATC Code G03DA04
DrugBank ID DB00396
KEGG ID D00066
MeSH ID D011374
PubChem ID 5994
TTD Drug ID D07BSQ
NDC Product Code 72189-217; 17478-766; 60722-3010; 51508-002; 51552-0006; 69543-373; 0009-0078; 70518-2560; 59651-153; 75882-923; 73309-164; 79572-029; 69543-375; 76420-070; 0009-5023; 71335-0835; 70700-286; 76420-058; 44911-0047; 69452-234; 64025-9801; 71335-0825; 12875-9937; 70518-3286; 43598-349; 38779-2309; 0023-6151; 59651-152; 11014-0425; 43742-0851; 50090-2527; 82393-102; 51508-007; 11014-0051; 38779-3169; 70934-914; 11014-0042; 65162-808; 51552-1279; 82653-004; 49452-6080; 38779-0043; 51552-1248; 60870-0248; 43598-350; 76420-059; 69452-149; 0009-0105; 71092-9974; 76420-072; 43742-1375; 51552-1066; 71205-903; 51552-0738; 62991-1124; 52671-012; 48087-0057; 76420-073; 60429-868; 71335-1990; 49452-6061; 65162-807; 55150-306; 0802-8063; 0143-9725; 71335-1913; 60687-611; 63323-261; 63629-8530; 72189-204; 82653-003; 52671-011; 69543-374; 0009-0052; 63629-7475; 50090-5928; 76420-682; 70518-3392; 43857-0120; 43647-134; 10888-8109; 77382-0050; 17478-767; 73377-048; 38779-0310; 49452-6079; 46144-101; 69543-372; 12875-9242; 38779-0057; 43857-0103; 51552-0829; 82018-0012; 16637-0030; 71335-1430; 68981-005; 38779-3247; 0591-3128; 63275-9921; 11014-0189; 43857-0084; 70700-162; 60592-607; 51927-5124; 16637-0040; 10888-8110; 63083-1538; 11014-0039; 11014-0043; 76420-071; 48087-0105; 16714-158; 38779-2708; 71205-293; 55566-6500; 51927-0009; 50090-3240; 69452-233; 0009-0081; 50090-4656; 51927-1046; 60429-869; 76420-683; 82018-0014; 16714-157; 51927-9017; 22552-0049; 71335-1432; 71335-1406; 69452-148; 70700-163; 55714-9004; 53002-1760; 77382-0030; 71335-1443; 71205-902; 0009-5620; 82018-0011; 0023-6150
Synonyms Progesterone | Pregnenedione | Progesterone, (17 alpha)-Isomer | Progesterone, (9 beta,10 alpha)-Isomer | Progesterone, (13 alpha,17 alpha)-(+-)-Isomer
Chemical Information
Molecular Formula C21H30O2
CAS Registry Number 57-83-0
SMILES CC(=O)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Blood luteinising hormone increasedAngiotensinogenP01019T644858462463; 10537146; 8119137; 7507825; 2293982; 8680436; 9725714; 7484438
Blood luteinising hormone increasedLutropin-choriogonadotropic hormone receptorP22888T794738462463; 10537146; 8119137; 7507825; 2293982; 8680436; 9725714; 7484438
Blood luteinising hormone increasedProgonadoliberin-1P01148T189508462463; 10537146; 8119137; 7507825; 2293982; 8680436; 9725714; 7484438
Cytogenetic abnormalityMitogen-activated protein kinase 1P28482T5897026062636
Cytogenetic abnormalityRAF proto-oncogene serine/threonine-protein kinaseP09560Not Available8321223; 8335690; 8822207; 14507918; 9245517; 8007949; 8949882; 1530949
Cytogenetic abnormalityMitogen-activated protein kinase 1P28482T589708321223; 8335690; 8822207; 14507918; 9245517; 8007949; 8949882; 1530949
Hormone level abnormalRetinol-binding protein 1P09455Not Available3036474; 14614773; 7679398
LeiomyomaCatenin beta-1P35222T8279526251118
LeiomyomaProto-oncogene Wnt-1P04628Not Available26251118
Reticuloendothelial disorders NECHigh affinity cationic amino acid transporter 1P30825Not Available26062636
Reticuloendothelial disorders NECMitogen-activated protein kinase 3P27361T2327626062636
Reticuloendothelial disorders NECMitogen-activated protein kinase 1P28482T589708321223; 8335690; 8822207; 14507918; 9245517; 8007949; 8949882; 1530949
Reticuloendothelial disorders NECProtein kinase C alpha typeP17252T1280826062636
Reticuloendothelial disorders NECMitogen-activated protein kinase 1P28482T5897026062636
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mental disability26.01.01.001--Not Available
Mental impairment19.21.02.003; 17.03.03.002--Not Available
Metrorrhagia21.01.01.006--Not Available
Migraine24.03.05.003; 17.14.02.0010.000884%Not Available
Mood swings19.04.03.0010.000589%Not Available
Muscle spasms15.05.03.0040.002357%
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myopathy15.05.05.001--Not Available
Nasal congestion22.04.04.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.0010.005009%
Neck pain15.03.04.0090.001179%
Neoplasm16.16.02.001--Not Available
Neoplasm malignant16.16.01.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Neuritis17.09.03.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Night sweats23.02.03.006; 08.01.03.0310.000589%Not Available
Nocturia20.02.03.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.000589%
Optic neuritis17.04.05.001; 10.04.10.002; 06.04.08.002--Not Available
Osteoarthritis15.01.04.001--Not Available
Ovarian cancer21.11.01.003; 16.12.04.001--Not Available
Ovarian cyst16.04.03.001; 21.11.01.002--Not Available
Ovarian enlargement21.11.02.0010.000589%Not Available
Ovarian failure21.11.02.005; 05.05.01.012--Not Available
Ovarian hyperstimulation syndrome21.11.02.007; 05.05.01.0130.009135%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 12 Pages